Institutional shares held 123 Million
305K calls
121K puts
Total value of holdings $228M
$567K calls
$224K puts
Market Cap $123M
65,950,200 Shares Out.
Institutional ownership 186.05%
# of Institutions 88


Latest Institutional Activity in CTMX

Top Purchases

Q2 2025
Vr Adviser, LLC Shares Held: 14M ($26M)
Q2 2025
Orbimed Advisors LLC Shares Held: 8.46M ($15.7M)
Q2 2025
Commodore Capital LP Shares Held: 7.69M ($14.3M)
Q2 2025
Perceptive Advisors LLC Shares Held: 6.99M ($13M)
Q2 2025
Vivo Capital, LLC Shares Held: 5.77M ($10.7M)

Top Sells

Q2 2025
Millennium Management LLC Shares Held: 233K ($434K)
Q2 2025
Acadian Asset Management LLC Shares Held: 1.56M ($2.9M)
Q2 2025
Congress Park Capital LLC Shares Held: 95.4K ($177K)
Q2 2025
Bank Of America Corp Shares Held: 4.77K ($8.87K)
Q2 2025
Prosight Management, LP Shares Held: 3.52M ($6.54M)

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.


Insider Transactions at CTMX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
981K Shares
From 9 Insiders
Exercise of conversion of derivative security 303K shares
Grant, award, or other acquisition 678K shares
Sell / Disposition
190K Shares
From 6 Insiders
Open market or private sale 190K shares

Track Institutional and Insider Activities on CTMX

Follow CytomX Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CTMX shares.

Notify only if

Insider Trading

Get notified when an Cytom X Therapeutics, Inc. insider buys or sells CTMX shares.

Notify only if

News

Receive news related to CytomX Therapeutics, Inc.

Track Activities on CTMX